Mind Medicine Inc.

Psychedelic biotech company $MNMD gapped up last week after the FDA granted breakthrough designation to its MM120 program for the treatment of generalized anxiety disorder. On the same day the company announced plans for an underwritten offering of 16,666,667 common shares at $6.00, as well as share purchase agreements for a concurrent private placement of 12.5M common shares at a price of $6.00 per common share.

Share This Article

 

About the Author

Mind Medicine Inc.

Joey Ramson